vs
Farmmi, Inc.（FAMI）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Farmmi, Inc.的季度营收约是Protalix BioTherapeutics, Inc.的1.8倍（$16.1M vs $9.1M），Farmmi, Inc.净利率更高（-0.3% vs -60.3%，领先60.1%），Protalix BioTherapeutics, Inc.同比增速更快（-49.9% vs -55.7%），Farmmi, Inc.自由现金流更多（$14.6M vs $1.6M）
Farmmi, Inc.是一家经营农产品加工与销售业务的跨国企业，核心业务包括香菇、木耳等多种食用真菌的培育与市场推广，产品品类涵盖竹荪、栗蘑、舞茸、猴头菇等多个品种。公司旗下运营Farmmi Jicai线上店铺，推出Forasen、Farmmi Liangpin品牌的食用菌产品，同时对外出口整朵干香菇与切片干香菇。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
FAMI vs PLX — 直观对比
营收规模更大
FAMI
是对方的1.8倍
$9.1M
营收增速更快
PLX
高出5.8%
-55.7%
净利率更高
FAMI
高出60.1%
-60.3%
自由现金流更多
FAMI
多$12.9M
$1.6M
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.1M | $9.1M |
| 净利润 | $-44.0K | $-5.5M |
| 毛利率 | 5.0% | 49.4% |
| 营业利润率 | -4.1% | -51.1% |
| 净利率 | -0.3% | -60.3% |
| 营收同比 | -55.7% | -49.9% |
| 净利润同比 | -107.0% | -184.8% |
| 每股收益（稀释后） | $-0.04 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FAMIPLX
| Q4 25 | — | $9.1M | ||
| Q3 25 | — | $17.9M | ||
| Q2 25 | — | $15.7M | ||
| Q1 25 | $16.1M | $10.1M | ||
| Q4 24 | — | $18.2M | ||
| Q3 24 | — | $18.0M | ||
| Q2 24 | — | $13.5M | ||
| Q1 24 | $36.4M | — |
净利润FAMIPLX
| Q4 25 | — | $-5.5M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $164.0K | ||
| Q1 25 | $-44.0K | $-3.6M | ||
| Q4 24 | — | $6.5M | ||
| Q3 24 | — | $3.2M | ||
| Q2 24 | — | $-2.2M | ||
| Q1 24 | $630.5K | — |
毛利率FAMIPLX
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | 5.0% | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | 5.9% | — |
营业利润率FAMIPLX
| Q4 25 | — | -51.1% | ||
| Q3 25 | — | 11.9% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | -4.1% | -41.0% | ||
| Q4 24 | — | 39.6% | ||
| Q3 24 | — | 22.2% | ||
| Q2 24 | — | -18.0% | ||
| Q1 24 | 2.5% | — |
净利率FAMIPLX
| Q4 25 | — | -60.3% | ||
| Q3 25 | — | 13.2% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | -0.3% | -35.8% | ||
| Q4 24 | — | 35.6% | ||
| Q3 24 | — | 18.0% | ||
| Q2 24 | — | -16.4% | ||
| Q1 24 | 1.7% | — |
每股收益（稀释后）FAMIPLX
| Q4 25 | — | $-0.06 | ||
| Q3 25 | — | $0.03 | ||
| Q2 25 | — | $0.00 | ||
| Q1 25 | $-0.04 | $-0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $0.03 | ||
| Q2 24 | — | $-0.03 | ||
| Q1 24 | $1.20 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $166.4M | $48.2M |
| 总资产 | $230.4M | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FAMIPLX
| Q4 25 | — | $14.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $17.9M | ||
| Q1 25 | — | $19.5M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | — | $23.4M | ||
| Q1 24 | — | — |
股东权益FAMIPLX
| Q4 25 | — | $48.2M | ||
| Q3 25 | — | $52.9M | ||
| Q2 25 | — | $49.9M | ||
| Q1 25 | $166.4M | $45.2M | ||
| Q4 24 | — | $43.2M | ||
| Q3 24 | — | $32.4M | ||
| Q2 24 | — | $28.6M | ||
| Q1 24 | $164.4M | — |
总资产FAMIPLX
| Q4 25 | — | $82.3M | ||
| Q3 25 | — | $82.3M | ||
| Q2 25 | — | $78.5M | ||
| Q1 25 | $230.4M | $73.9M | ||
| Q4 24 | — | $73.4M | ||
| Q3 24 | — | $61.6M | ||
| Q2 24 | — | $91.5M | ||
| Q1 24 | $171.9M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.6M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | $14.6M | $1.6M |
| 自由现金流率自由现金流/营收 | 90.1% | 17.8% |
| 资本支出强度资本支出/营收 | 0.1% | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-13.6M |
8季度趋势，按日历期对齐
经营现金流FAMIPLX
| Q4 25 | — | $2.0M | ||
| Q3 25 | — | $-3.7M | ||
| Q2 25 | — | $-5.2M | ||
| Q1 25 | $14.6M | $-5.1M | ||
| Q4 24 | — | $4.0M | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | — | $-3.6M | ||
| Q1 24 | $-14.9M | — |
自由现金流FAMIPLX
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | $14.6M | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
自由现金流率FAMIPLX
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | 90.1% | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
资本支出强度FAMIPLX
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | 0.1% | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | 0.0% | — |
现金转化率FAMIPLX
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | -23.63× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FAMI
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
